GlassScriptPhysician profile
Julie M Mclaughlin
NPI 1245589092
$141,806.12
in general payments reported to CMS, 2019-2025
20 companies · $59K in 2025
The $59K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $406 · 2020: $68.57 · 2021: $331 · 2022: $5,740 · 2023: $17K · 2024: $59K · 2025: $59K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $73K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Consulting Fee: $16K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $15K · Travel and Lodging: $14K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $73,012.11 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,015.00 |
| Consulting Fee | $16,290.47 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $14,925.00 |
| Travel and Lodging | $14,017.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis Be INC | $72,844.06 | 2022-2025 | Optilight, M22 |
| Biotissue Holdings INC. | $38,926.21 | 2020-2025 | |
| Tarsus Pharmaceuticals, INC. | $21,347.04 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $5,833.99 | 2019-2025 | Cequa, Xelpros, Bromsite |
| Abbvie INC. | $1,473.02 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $274.37 | 2019-2022 | |
| Alcon Vision LLC | $247.97 | 2021-2025 | Argos, Clareon, Eysuvis |
| Oyster Point Pharma, INC. | $247.90 | 2022-2025 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $129.63 | 2019-2021 | |
| Allergan, INC. | $100.62 | 2019-2020 | |
| Coopervision INC. | $97.62 | 2024 | Clariti Contact Lens |
| Bausch & Lomb Americas INC. | $90.72 | 2024-2025 | Miebo, Xiidra |
| Harrow Eye, LLC | $50.07 | 2025 | Vevye |
| Eyevance Pharmaceuticals LLC | $29.69 | 2022-2023 | Flarex |
| Kala Pharmaceuticals, INC. | $24.40 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $21.03 | 2023 | Vabysmo |
| Quidel Corporation | $17.92 | 2019 | |
| Thea Pharma INC. | $17.65 | 2024 | Iyuzeh |
| Dompe US, INC. | $16.72 | 2022 | |
| Amgen INC. | $15.49 | 2024 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Mclaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.